Can-Fite releases Namodenoson treatment data for pancreatic and liver cancer at Bio Europe Conference.
Can-Fite BioPharma Ltd. releases data on Namodenoson treatment for pancreatic and liver cancer at Bio Europe Conference. Their pipeline includes Namodenoson for advanced liver and pancreatic cancer, which has been licensed to various companies such as Ewopharma for Eastern Europe, CMS in China, and CKD in South Korea. Can-Fite focuses on clinical development and partnering with companies specializing in pharmaceutical distribution.
March 11, 2024
3 Articles